Research Analysts’ Weekly Ratings Updates for Guardant Health (GH)

Several analysts have recently updated their ratings and price targets for Guardant Health (NASDAQ: GH):

• 7/16/2026 – Guardant Health had its price target raised by Guggenheim from $160.00 to $190.00. They now have a “buy” rating on the stock.
• 7/14/2026 – Guardant Health had its price target raised by Canaccord Genuity Group Inc. from $135.00 to $205.00. They now have a “buy” rating on the stock.
• 7/9/2026 – Guardant Health had its price target raised by Morgan Stanley from $130.00 to $175.00. They now have an “overweight” rating on the stock.
• 7/8/2026 – Guardant Health had its price target raised by Citigroup Inc. from $150.00 to $215.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Guardant Health had its “outperform” rating reaffirmed by Evercore Inc. They now have a $200.00 price target on the stock.
• 7/6/2026 – Guardant Health had its price target raised by Bank of America Corporation from $135.00 to $190.00. They now have a “buy” rating on the stock.
• 7/2/2026 – Guardant Health had its “buy” rating reaffirmed by TD Cowen.
• 7/2/2026 – Guardant Health had its price target raised by Sanford C. Bernstein from $175.00 to $200.00. They now have an “outperform” rating on the stock.
• 7/1/2026 – Guardant Health had its price target raised by BTIG Research from $160.00 to $190.00. They now have a “buy” rating on the stock.
• 6/29/2026 – Guardant Health had its price target raised by Guggenheim from $135.00 to $160.00. They now have a “buy” rating on the stock.
• 6/26/2026 – Guardant Health is now covered by Sanford C. Bernstein. They set an “outperform” rating and a $175.00 price target on the stock.
• 6/25/2026 – Guardant Health was upgraded by Sanford C. Bernstein to “strong-buy”.
• 6/24/2026 – Guardant Health was given a new $150.00 price target by UBS Group AG.
• 6/24/2026 – Guardant Health had its price target raised by Barclays PLC from $120.00 to $150.00. They now have an “overweight” rating on the stock.
• 6/11/2026 – Guardant Health is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $185.00 price target on the stock.
• 6/11/2026 – Guardant Health is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $185.00 price target on the stock.
• 6/8/2026 – Guardant Health had its price target raised by Mizuho from $135.00 to $175.00. They now have an “outperform” rating on the stock.
• 6/5/2026 – Guardant Health is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $165.00 price target on the stock.
• 6/5/2026 – Guardant Health is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $165.00 price target on the stock.
• 6/2/2026 – Guardant Health was upgraded by Evercore Inc from “in-line” to “outperform”. They now have a $160.00 price target on the stock.
• 6/2/2026 – Guardant Health is now covered by Wolfe Research. They set an “outperform” rating and a $150.00 price target on the stock.
• 6/1/2026 – Guardant Health was upgraded by Wolfe Research to “strong-buy”.
• 5/28/2026 – Guardant Health was downgraded by Guggenheim from “buy” to “buy”.
• 5/27/2026 – Guardant Health was given a new $160.00 price target by BTIG Research. They now have a “buy” rating on the stock.
• 5/26/2026 – Guardant Health had its price target raised by BTIG Research from $145.00 to $155.00. They now have a “buy” rating on the stock.
• 5/21/2026 – Guardant Health was given a new $127.00 price target by Piper Sandler.
• 5/21/2026 – Guardant Health had its “buy” rating reaffirmed by TD Cowen.

Insider Transactions at Guardant Health

In other news, insider John G. Saia sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $106.51, for a total value of $2,130,200.00. Following the sale, the insider owned 45,950 shares of the company’s stock, valued at $4,894,134.50. The trade was a 30.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Meghan V. Joyce sold 10,000 shares of Guardant Health stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $126.98, for a total transaction of $1,269,800.00. Following the completion of the transaction, the director owned 11,183 shares of the company’s stock, valued at $1,420,017.34. This represents a 47.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 708,565 shares of company stock valued at $90,556,597. 5.60% of the stock is currently owned by insiders.

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.